4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer: Toward the Rapid Assessment of Therapy EfficacyBOTTINI, Alberto; BERRUTI, Alfredo; GENERALI, Daniele et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, issn 1052-6773, 101 p.Conference Proceedings

New Omics Information for Clinical Trial Utility in the Primary SettingDAMIA, Giovanna; BROGGINI, Massimo; MARSONI, Silvia et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 128-133, issn 1052-6773, 6 p.Conference Paper

Predictive Immunohistochemical Biomarkers in the Context of Neoadjuvant Therapy for Breast CancerGENERALI, Daniele; SYMMANS, William F; BERRUTI, Alfredo et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 99-102, issn 1052-6773, 4 p.Conference Paper

Mechanisms of Resistance to HER2 Target TherapyTORTORA, Giampaolo.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 95-98, issn 1052-6773, 4 p.Conference Paper

Overcoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in the short-term future?MARGARITI, Nadia; FOX, Stephen B; BOTTINI, Alberto et al.Breast cancer research and treatment. 2011, Vol 128, Num 3, pp 599-606, issn 0167-6806, 8 p.Article

Neoadjuvant Chemotherapy and Targeted Therapies: a Promising StrategyMETZGER-FILHO, Otto; DE AZAMBUJA, Evandro.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 116-119, issn 1052-6773, 4 p.Conference Paper

kConFab: A Familial Breast Cancer Consortium Facilitating Research and Translational OncologyTHORNE, Heather; MITCHELL, Gillian; FOX, Stephen et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 79-81, issn 1052-6773, 3 p.Conference Paper

Biomarkers Predicting Clinical Benefit: Fact or Fiction?GUARNERI, Valentina; BARBIERI, Elena; CONTE, Pierfranco et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 63-66, issn 1052-6773, 4 p.Conference Paper

Neoadjuvant Chemotherapy: Early Response as a Guide for Further Treatment: Clinical, Radiological, and BiologicalUNTCH, Michael; VON MINCKWITZ, Gunter.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 138-141, issn 1052-6773, 4 p.Conference Paper

Bridging the Gap Between Translational Research and Clinical ApplicationMILLER, William R; LARIONOV, Alexey A.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 134-137, issn 1052-6773, 4 p.Conference Paper

Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer PatientsBERRUTI, Alfredo; GENERALI, Daniele; BERTAGLIA, Valentina et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 142-146, issn 1052-6773, 5 p.Conference Paper

Molecular Oncology and the Neoadjuvant Setting: the Perfect Blend for Treatment Personalization and Clinical Trial DesignGENERALI, Daniele; BERRUTI, Alfredo; BOTTINI, Alberto et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 67-70, issn 1052-6773, 4 p.Conference Paper

The G-Protein―Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor PrognosisNIKITENKO, Leonid L; LEEK, Russell; HARRIS, Adrian L et al.Clinical cancer research (Print). 2013, Vol 19, Num 20, pp 5740-5748, issn 1078-0432, 9 p.Article

Synergistic activity of letrozole and sorafenib on breast cancer cellsBONELLI, Mara A; FUMAROLA, Claudia; EVANS, Dean B et al.Breast cancer research and treatment. 2010, Vol 124, Num 1, pp 79-88, issn 0167-6806, 10 p.Article

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancerGENERALI, Daniele; FOX, Stephen B; CAMPO, Leticia et al.Clinical cancer research. 2007, Vol 13, Num 2, pp 550-558, issn 1078-0432, 9 p., 1Article

The HER2 World: Better Treatment Selection for Better OutcomeTAGLIABUE, Elda; CAMPIGLIO, Manuela; PUPA, Serenella M et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 82-85, issn 1052-6773, 4 p.Conference Paper

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patientsMELE, Teresa; GENERALI, Daniele; DOGLIOTTI, Luigi et al.Breast cancer research and treatment. 2010, Vol 123, Num 3, pp 795-804, issn 0167-6806, 10 p.Article

Immunomodulation of FOXP3⁺ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer PatientsGENERALI, Daniele; BATES, Gaynor; DOGLIOTTI, Luigi et al.Clinical cancer research (Print). 2009, Vol 15, Num 3, pp 1046-1051, issn 1078-0432, 6 p.Article

Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapyBODINI, Maria; BERRUTI, Alfredo; AGUGGINI, Sergio et al.Breast cancer research and treatment. 2004, Vol 85, Num 3, pp 211-218, issn 0167-6806, 8 p.Article

Gene Profiling Assay and Application: The Predictive Role in Primary TherapyFUMAGALLI, Debora; DESMEDT, Christine; IGNATIADIS, Michail et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 124-127, issn 1052-6773, 4 p.Conference Paper

Tissue and Soluble Biomarkers in Breast Cancer and Their Applications: Ready to Use?DANOVA, Marco; DELFANTI, Sara; MANZONI, Mariangela et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 75-78, issn 1052-6773, 4 p.Conference Paper

Strategies to Translate Preclinical Information to Breast Cancer Patient BenefitDAIDONE, Maria Grazia; ZAFFARONI, Nadia; CAPPELLETTI, Vera et al.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 55-59, issn 1052-6773, 5 p.Conference Paper

Phosphorylated ERa, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast CancerGENERALI, Daniele; BUFFA, Francesca M; PAPOTTI, Mauro et al.Journal of clinical oncology. 2009, Vol 27, Num 2, pp 227-234, issn 0732-183X, 8 p.Article

The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor loadGENERALI, Daniele; BERRUTI, Alfredo; BOTTINI, Alberto et al.Bone (New York, NY). 2007, Vol 40, Num 1, pp 182-188, issn 8756-3282, 7 p.Article

Hypoxia-lnducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancerGENERALI, Daniele; BERRUTI, Alfredo; GANDOLFI, Valeria et al.Clinical cancer research. 2006, Vol 12, Num 15, pp 4562-4568, issn 1078-0432, 7 p.Article